NasdaqCM - Delayed Quote • USD
Viridian Therapeutics, Inc. (VRDN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
314.00
314.00
1,772.00
2,963.00
1,050.00
Operating Expense
254,764.00
254,764.00
136,076.00
82,691.00
41,569.00
Operating Income
-254,450.00
-254,450.00
-134,304.00
-79,728.00
-40,519.00
Net Non Operating Interest Income Expense
16,716.00
16,716.00
4,430.00
315.00
-335.00
Other Income Expense
--
--
--
--
-69,861.00
Pretax Income
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-110,715.00
Net Income Common Stockholders
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-110,715.00
Diluted NI Available to Com Stockholders
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-110,715.00
Basic EPS
-5.14
-5.31
-4.05
-6.66
-31.13
Diluted EPS
-5.14
-5.31
-4.05
-6.66
-31.13
Basic Average Shares
42,451.85
44,755.48
32,087.29
11,918.71
3,557.07
Diluted Average Shares
42,451.85
44,755.48
32,087.29
11,918.71
3,557.07
Total Operating Income as Reported
-254,450.00
-254,450.00
-134,304.00
-79,728.00
-110,380.00
Total Expenses
254,764.00
254,764.00
136,076.00
82,691.00
41,569.00
Net Income from Continuing & Discontinued Operation
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-110,715.00
Normalized Income
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-40,854.00
Interest Income
18,563.00
18,563.00
4,916.00
318.00
173.00
Interest Expense
1,847.00
1,847.00
486.00
3.00
508.00
Net Interest Income
16,716.00
16,716.00
4,430.00
315.00
-335.00
EBIT
-235,887.00
-235,887.00
-129,388.00
-79,410.00
-110,207.00
EBITDA
-235,365.00
-235,365.00
-129,133.00
-79,290.00
-109,968.00
Reconciled Depreciation
522.00
522.00
255.00
120.00
239.00
Net Income from Continuing Operation Net Minority Interest
-237,734.00
-237,734.00
-129,874.00
-79,413.00
-110,715.00
Total Unusual Items Excluding Goodwill
--
--
--
--
-69,861.00
Total Unusual Items
--
--
--
--
-69,861.00
Normalized EBITDA
-235,365.00
-235,365.00
-129,133.00
-79,290.00
-40,107.00
12/31/2020 - 6/18/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
SLRN Acelyrin, Inc.
4.2400
0.00%
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
IMVT Immunovant, Inc.
27.17
-2.09%
COGT Cogent Biosciences, Inc.
6.02
+0.17%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
TRML Tourmaline Bio, Inc.
15.68
-2.00%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%